This new technology could one day significantly expand the market for gene-editing biotechs.

The company's innovative qualities may pay rich dividends down the road.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your ...

Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.

Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the University of British Columbia are extending those possibilities to the skin for ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

New research shows it’s possible to edit the DNA of human embryos with more precision. But scientists warn it’s still not ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

CRISPR Therapeutics focuses on developing gene-based medicines using its proprietary CRISPR/Cas9 platform. The company develops gene-based medicines, a transformative part of healthcare stocks. It ...